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Abstract
Background: Increment of compound muscle action potential amplitude is a diagnos-
tic hallmark of Lambert-Eaton myasthenic syndrome (LEMS). Making a diagnosis can
be challenging, therefore, a proper cutoff for abnormal increment is highly relevant
for improved recognition of this rare disease.
Methods: We determined the sensitivity and specificity of 60% and 100% cutoff
values in all consecutive patients who underwent increment testing in our hospital
from 1999 to 2016.
Results:We included 156 patients, 63 with LEMS and 93 without LEMS. Sensitivity of
a 60% cutoff for increment testing was 77.8% (95% confidence interval 65.5%–87.3%)
and 58.7% (45.6%–71.0%) for 100%. Specificity was 98.9% (94.2%–100%) and 100%
(96.1%–100%) using a threshold of 60% and 100%, respectively.
Conclusions: Lowering the cutoff value for abnormal increment to 60% greatly
increases sensitivity to diagnose LEMS without an overt loss in specificity.
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1 | INTRODUCTION
Repetitive nerve stimulation (RNS) and increment testing are the most
important electrophysiological tests to diagnose Lambert-Eaton myas-
thenic syndrome (LEMS).1,2 Typical findings include a triad of low
compound muscle action potential (CMAP) amplitude at rest, decre-
ment upon low-frequency repetitive nerve stimulation and an increase
or “increment” of the CMAP amplitude after 10–30 s of exercise or
upon high-rate stimulation.2,3 Historically, 100% increment of this
CMAP amplitude has been used as a cutoff for diagnosis of LEMS.2,3
Although highly specific, sensitivity using this threshold is limited,
dependent on the number of muscles tested.4–6 Because making a
diagnosis can be challenging, an optimal cutoff value for abnormal
increment is highly relevant for improved recognition of this rare
disease.
One study reported a 60% cutoff threshold for abnormal incre-
ment to increase sensitivity of this test, while maintaining specificity
when compared with myasthenia gravis (MG).4 However, since its
publication, several studies have still variably used either a 60%3,7 or
100%8–10 cutoff in diagnostic criteria. We, therefore, compared diag-
nostic characteristics of 60% and 100% increment thresholds in the
diagnosis of LEMS in a second, independent cohort of patients.
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2 | METHODS
2.1 | Patients
We retrospectively studied all consecutive patients who underwent
RNS as well as increment testing from 1999 to 2016 at the Leiden
University Medical Center, during a diagnostic evaluation of patients
in whom LEMS was part of the differential diagnosis.
2.2 | Diagnostic criteria
Diagnosis of LEMS is usually based on fluctuating muscle weakness,
decreased tendon reflexes and autonomic symptoms, supported by
either presence of antibodies to voltage-gated calcium channels
(VGCC) or abnormal decrement and increment upon RNS.2 Because
abnormal increment is the subject of the current study, this criterion
cannot be used. Therefore, for this study, diagnosis was based on fluc-
tuating muscle weakness, decreased tendon reflexes, and abnormal
decrement, supported by either presence of antibodies to VGCC or
prominent autonomic symptoms.
2.3 | Electrodiagnostic testing
Patients were asked to refrain from using 3,4-diaminopyridine or
pyridostigmine at least 12 h before investigation, although this was
not enforced. RNS was administered as trains of 10 stimuli at 1, 3,
and 5 Hz using a Nicolet Viking IV machine (Nicolet Medical, Madison,
WI) until 2004 and a Medelec Synergy 11.0 (Oxford Instruments,
Abingdon, Oxfordshire, UK) thereafter. The optimal stimulation site
on the skin was identified using inframaximal stimuli and the limit of
supramaximal intensity was established. The working intensity was
130% of that threshold. RNS was performed on the hypothenar,
nasalis, and trapezius muscles.11–13 Abnormal decrement was defined
as at least 10% decrease in amplitude of the lowest CMAP of the train
compared with the first CMAP.1,11,12 The increment test involved
acquiring a baseline CMAP at rest, followed by the first CMAP ampli-
tude measured immediately after 10 or 30 s of voluntary contraction.
Abnormal increment was defined as either 60 or 100% increase in
CMAP amplitude after contraction. High-rate RNS was not routinely
performed.
All tests were performed with a skin temperature of at least
32C. Quality criteria for RNS and increment testing were12: (1) the
stimulus artefact should return to baseline before onset of the CMAP;
(2) the CMAP should begin with a negative phase or an initial positive
phase smaller than approximately one-fourth of the amplitude of the
negative phase; (3) the CMAP waveform should be essentially
biphasic; and (4) the amplitude of the negative phase of the CMAP
should preferably be over 1 mV. In case of lower amplitudes, we
enforced all other quality criteria scrupulously. Technically inadequate
investigations were excluded.
2.4 | Statistics
Sensitivity and specificity are reported as percentages with 95% confi-
dence intervals (CI), and calculated using SPSS version 24.0 (Chicago,
IL) and Graphpad Prism 7 (La Jolla, CA).
3 | RESULTS
Increment testing was performed in 164 patients during the study
period, of whom 156 were ultimately analyzed, including 63 LEMS
patients (Table 1; Supporting Information Figure S1 flowchart for
inclusion and disease groups, which is available online). The hypothe-
nar muscle was tested in all but four patients (97.5%). The nasalis
muscles were tested in 19 patients (11.7%), while tibialis anterior, tra-
pezius, and abductor pollicis brevis muscles were tested in one
patient each.
Sensitivity and specificity are reported in Table 2, showing
increased sensitivity for the 60% as compared to the 100% cutoff.
Exclusion of three seronegative LEMS patients with typical clinical
symptoms (including prominent autonomic symptoms) resulted in a
sensitivity of 80.0% (67.7%–89.2%) for a 60% increment threshold
and 61.7% (48.2%–73.4%) using a 100% threshold. Limiting the con-
trol group only to 23 patients with myasthenia gravis and congenital
myasthenic syndromes, specificity was 95.7% for the 60% threshold
and 100% for the 100% threshold. The single false positive patient
TABLE 1 Baseline characteristics
Baseline Patients Gender (M/F) Median age (range; y) Thymoma (%) SCLC (%) Abnormal decrement (%)
LEMS 63 30/33 56.0 (14–85) 0 (0%) 17 (27.0%) 60/61a (98.3%)
AChR MG 16 4/12 55.9 (16–77) 2 (12.5%) 0 (0%) 11 (68.8%)
Other myasthenia 7 5/2 52.4 (23–84) 0 (0%) 0 (0%) 3 (42.9%)
Other NMD 35 15/20 59.3 (30–83) n.a. n.a. 2 (5.7%)
no NMD 35 15/20 58.9 (38–75) n.a. n.a. 0 (0%)
Abbreviations: AChR MG, acetylcholine receptor antibody-positive myasthenia gravis; LEMS, Lambert-Eaton myasthenic syndrome; MuSK MG,
muscle-specific kinase antibody-positive myasthenia gravis; n.a., data not available; NMD, neuromuscular disease; SCLC, small cell lung cancer.
aPresence of abnormal decrement not tested for two LEMS patients at the time of investigation.
2 LIPKA ET AL.
had a normal initial CMAP amplitude, 56% decrement and 68% incre-
ment in the hypothenar muscle. She had generalized MG with acetyl-
choline receptor (AchR) antibodies and a severe axonal
polyneuropathy.
Sensitivity was higher in the 18 untreated LEMS patients, and in
LEMS patients without associated lung cancer for the 60% cutoff
(Supporting Information Table S1). Of three seronegative LEMS
patients with typical clinical symptoms who were already treated
symptomatically, one had a clinically meaningful increment (95%) in
the hypothenar muscle.
Increment in nasalis muscles was mainly tested in patients with
ocular or facial weakness (in 11 of 17 patients) or low CMAP amplitude
of the nasalis muscle (10/17). This resulted in detection of >100% incre-
ment in two patients without increment in the hypothenar muscle.
4 | DISCUSSION
In this study, we confirm that a 60% threshold for increment greatly
increases sensitivity while maintaining a high specificity in a large
group of LEMS patients and a different control group than previously
studied.4
Specificity of increment for LEMS using either threshold was very
high. False-positive increment was present in one otherwise typical
AChR MG patient and could be pseudo-facilitation or related to the
low CMAP amplitude (2.8 mV). Lowering the threshold to 60%, there-
fore, facilitates the diagnosis of LEMS, which may eliminate the need
for additional testing such as high-frequency stimulation, which can
be quite painful, and may hasten diagnosis. We used a practical
approach and mainly tested the hypothenar muscle, which is likely to
be the most reliable and sensitive muscle for detecting increment.5,6
Additional testing of the nasalis muscle was only performed when
clinically appropriate. In contrast to the previous study of Oh et al.,
our study tested not only MG patients, but also several other patients
in whom neuromuscular junction disorders were suspected.4
Several previous studies have described diagnostic characteristics
of increment testing. Oh et al. also showed an increase in sensitivity
from 85% to 97% when lowering the cutoff threshold to 60% in
34 LEMS patients.4 This study had a more strict definition of LEMS
diagnosis, possibly selecting for a more severe subgroup. Increment
was tested in the hypothenar muscle both at high-rate stimulation
(HRS) and after voluntary contraction. Specificity of a 60% threshold
was still 99% using a larger population of 538 MG patients, but was
not tested in other control groups. A follow-up study comparing sero-
positive and seronegative LEMS patients showed a 60% increment
cutoff is especially important for seronegative LEMS patients, in
whom increment is less prominent.14 Another study including
10 LEMS patients also reported 50% increment might be sufficient
and more sensitive than the 100% threshold for LEMS diagnosis,
reporting less than 50% increment in all muscles in controls.6
Other studies have focused on duration of exercise before incre-
ment testing, as well as comparison with HRS (20–50 Hz). Most inves-
tigations in our study were performed after 30 s, while a previous
study suggested that 10 s might be more sensitive.15 Previous studies
have shown conflicting results regarding diagnostic yield of increment
testing by either HRS or after exercise.3,4,16 As we mainly performed
postexercise stimulation, we could not analyze the diagnostic yield of
both thresholds using HRS.
Limitations include a lower overall sensitivity increment for LEMS
diagnosis compared with previous studies; several explanations are
likely to contribute to this difference. Most of our patients were
referred to our tertiary clinic for a second opinion. Therefore, many
patients were already treated at the time of electrophysiological test-
ing. In line with this, sensitivity in our study was considerably higher
in 18 untreated LEMS patients. In this group a threshold of 60% still
resulted in a large absolute increase in sensitivity. The limited number
of LEMS patients with an associated SCLC (27%) might also result
from referral bias. Previous studies of the diagnostic yield of incre-
ment testing often used a more extensive testing protocol, including
multiple muscle groups for most patients and/or testing both HRS as
well as increment after voluntary contraction.3–6
In conclusion, we confirm that lowering the cutoff value for
abnormal increment from 100% to 60% for diagnosis of LEMS greatly
increases sensitivity.4 Together with the results of the previous study
from Oh et al., we now have two heterogeneous studies, reaching the
same conclusion. We propose using a threshold for abnormal incre-
ment of 60%, as this should lead to improved diagnosis of patients
with this rare neuromuscular disease.
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